The clinical role of plasma P-tau217 in Alzheimer’s disease: a longitudinal study design

  • Previous studies suggest that plasma P-tau217 is a promising marker of preclinical Alzheimer’s disease (AD).
  • Expanding these findings, the current study found that among the plasma biomarkers (P-tau181, P-tau217, P-tau231) evaluated in the Swedish BioFINDER-1 and Wisconsin Registry for Alzheimer Prevention (WRAP) cohorts of cognitively unimpaired individuals, P-tau217 predicts cognitive decline in patients with preclinical AD.
  • The authors confirmed that plasma P-tau217 can be used as a biomarker that complements cerebrospinal fluid or positron emission tomography for patient selection to monitor disease-modifying treatments in clinical trials.